Navigation Links
Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
Date:8/7/2017

NDA Partners Chairman Carl Peck, MD, announced today that Dr. Michael A. Eldon, the former Vice President of Clinical Pharmacology at Nektar Therapeutics, and a clinical pharmacology, pharmacokinetics/pharmacodynamics and pharmacometrics expert with more than thirty-five years of experience in the pharmaceutical industry, has joined the firm as an Expert Consultant.

As Vice President of Clinical Pharmacology at Nektar Therapeutics, Dr. Eldon was responsible for clinical and preclinical pharmacokinetics, ADME, pharmacometrics and systems biology in drug development and discovery.

Prior to Nektar, Dr. Eldon worked at Parke-Davis Pharmaceutical Research where he participated in the development and registration of Lipitor (atorvastatin), Neurontin (gabapentin), Rezulin (troglitazone), Lyrica (pregabalin), Pro-Air (procaterol), Lopid (gemfibrozil), Loestrin (oral contraceptive), Estrostep (oral contraceptive), Procanbid (procainamide extended release), FemPatch (transdermal estradiol), Cerebyx (fosphenytoin), Penetrex (enoxacin), Zagam (sparfloxacin) and Nitrostat (nitroglycerin) stabilized tablets. While at Nektar, he participated in the discovery, development, and registration of Movantik and Exubera (rH insulin for inhalation); and the discovery and preclinical and clinical development of other Nektar proprietary products including Onzeald (etirinotecan pegol), NKTR-181, and NKTR-214.

“Dr. Eldon’s extensive experience in clinical pharmacology, PK/PD, and pharmacometrics make him an excellent resource for our clients in the preclinical and clinical drug development phases,” said Dr. Carl Peck. “We are very pleased he has joined NDA Partners.”

Dr. Eldon earned his doctorate degree in Biopharmaceutics and Pharmacokinetics and a Bachelors of Science degree in Pharmacy from the University of Cincinnati. He is a member of several pharmaceutical societies, is a Fellow of the American College of Clinical Pharmacology, and has authored over 150 scientific articles and presentations.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle@ndapartners.com

Read the full story at http://www.prweb.com/releases/2017/08/prweb14566581.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Former Associate Director of Product Development R&D at Allergan, Melissa Kirkegaard, joins NDA Partners as Expert Consultant
2. Former Vice President of Development Operations at XenoPort, Sami Karaborni, PhD, joins NDA Partners as Expert Consultant
3. Former CEO of Eurofins Advantar Laboratories, Richard Kenley, PhD, joins NDA Partners as Expert Consultant
4. Former FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
5. Former P&G VP Appointed New Industry Expert at Verixs Advisory Board
6. Former Director of FDA Division of Biostatistics, Gregory Campbell, PhD, joins NDA Partners as Expert Consultant
7. Vinod Shah, PhD, Former Senior Research Scientist in FDA Office of Pharmaceutical Sciences, Joins NDA Partners as Expert Consultant
8. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
9. Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners
10. Repetitive Head Injuries May Not Cause Movement Problems for Former NFL Players
11. Dr. Deborah Wenkert Pediatrics Expert and Former Amgen Clinical Research Medical Director, Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... of Hannah Holscher, PhD, RD, to its Scientific Advisory Board. Dr. Holscher is ... Nutrition and the Division of Nutritional Sciences at the University of Illinois Urbana-Champaign, ...
(Date:9/17/2019)... POWAY, Calif. (PRWEB) , ... September 17, 2019 , ... ... of osteoarthritis. At only four months old, Tucker was limping and lame on his ... hip and elbow dysplasia and it was called “the worst case the vet had ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for ... Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... educate about the latest developments in genome sequencing analysis. Check your local listings ... taking place at Rivermap Research & Consulting and will explore its revolutionary pathogenic ...
Breaking Biology Technology:
(Date:9/24/2019)... ... September 24, 2019 , ... A-Alpha Bio ... drug development, announced today that it has raised $2.8M from leading science-focused venture ... also includes AME Cloud Ventures, Boom Capital, Madrona Venture Group, Sahsen Ventures, Washington ...
(Date:9/17/2019)... ... ... VISTAAR released ADVISORY Playbooks to help small and mid-level companies who ... their internal strategies they formed for developing or launching new products or expanding to ... to change their product elements and want to know the impact, introducing new product ...
(Date:9/14/2019)... , ... September 12, 2019 , ... ... manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... company’s biologics business. Dr. Schaffer has played an integral advisory role on the ...
Breaking Biology News(10 mins):